Automated ECL Aptasensing Platform from an Intrarticular Radical Annihilation Route for Distinguishing Glioma Stages.

in Analytical chemistry by Jing-Yi Bao, Wen Liu, Can Chen, Hao-Tian Zhu, Ai-Jun Wang, Pei-Xin Yuan, Jiu-Ju Feng

TLDR

  • The study developed a new way to detect a tiny molecule called miRNA-182 in blood samples. They used a special kind of light called electrochemiluminescence (ECL) to detect the molecule. They found that their new way was better than the old way and could detect the molecule at very low levels. They also found that their new way could distinguish between different stages of a disease called glioma. This study highlights the potential of using advanced ECL luminophores and automatic methods to detect important molecules in blood samples.

Abstract

Nowadays, continuous efforts have been devoted to designing stable and high-efficiency electrochemiluminescence (ECL) emitters as alternatives for tris(2,2'-bipyridine)-ruthenium(II) (Ru(bpy)) in medical research. Herein, a novel ECL emitter was obtained by coordinating crystalline covalent triazinyl frameworks (cCTFs) with Ru(termed Ru-cCTFs), which exhibited strong ECL emission by the ligand to metal charge transfer (LMCT) route. After its integration with 4-mercaptopyridine (SH-Py), the resultant SH-Py-Ru-cCTFs achieved 2.3-fold enhancement in the ECL efficiency by employing Ru(bpy)as a standard, which involved a dynamic "intrarticular radical annihilation" ECL pathway. On such foundation, an automated ECL (A-ECL) aptasensor was constructed with an "on-off-on" model and magnetic separation upon linkage of the SH-Py-Ru-cCTFs with streptavidin (SA) magnetic beads (MBs). This automatic assay of miRNA-182 showed a wider linear range from 1.0 to 100.0 fM with a correlation coefficient () of 0.994, a lower limit of detection (LOD) down to 0.28 fM, and faster operation within 41 min. Impressively, this bioassay facilely distinguished the stages of glioma disease from clinical blood samples with high accuracy. Hence, this research sheds light on how to develop advanced ECL luminophores and an automatic method, showing substantial insights into pathogenesis research of gliomas.

Overview

  • The study focuses on designing stable and high-efficiency electrochemiluminescence (ECL) emitters as alternatives for tris(2,2'-bipyridine)-ruthenium(II) (Ru(bpy)) in medical research. The authors obtained a novel ECL emitter by coordinating crystalline covalent triazinyl frameworks (cCTFs) with Ru(termed Ru-cCTFs), which exhibited strong ECL emission by the ligand to metal charge transfer (LMCT) route. The study aims to achieve an automated ECL (A-ECL) aptasensor for the detection of miRNA-182 in clinical blood samples with high accuracy.

Comparative Analysis & Findings

  • The study compared the ECL efficiency of Ru-cCTFs with Ru(bpy)as a standard and found a 2.3-fold enhancement in the ECL efficiency by employing Ru(bpy)as a standard. The resultant SH-Py-Ru-cCTFs achieved a wider linear range from 1.0 to 100.0 fM with a correlation coefficient () of 0.994, a lower limit of detection (LOD) down to 0.28 fM, and faster operation within 41 min. The A-ECL aptasensor distinguished the stages of glioma disease from clinical blood samples with high accuracy.

Implications and Future Directions

  • The study's findings highlight the potential of developing advanced ECL luminophores and an automatic method for the detection of miRNA-182 in clinical blood samples. The A-ECL aptasensor could be used for the early diagnosis of glioma disease, which is a critical step in improving patient outcomes. Future research could focus on developing ECL luminophores for the detection of other miRNAs or exploring the use of ECL luminophores in other diseases. Additionally, the study's methodology could be used to develop other A-ECL aptasensors for the detection of other biomolecules.
Read Full Article